Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Arix Bioscience plc    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
01/12/2021 01/13/2021 01/14/2021 01/15/2021 01/18/2021 Date
205(c) 202(c) 208(c) 205(c) 196 Last
66 975 77 662 92 085 71 660 106 877 Volume
-1.44% -1.46% +2.97% -1.44% -4.39% Change
More quotes
Financials
Sales 2020 0,40 M 0,54 M 0,54 M
Net income 2020 -12,8 M -17,4 M -17,4 M
Net cash position 2020 69,1 M 93,8 M 93,8 M
P/E ratio 2020 -20,7x
Yield 2020 -
Sales 2021 0,35 M 0,48 M 0,48 M
Net income 2021 10,4 M 14,1 M 14,1 M
Net cash position 2021 157 M 214 M 214 M
P/E ratio 2021 25,6x
Yield 2021 -
Capitalization 268 M 364 M 364 M
EV / Sales 2020 496x
EV / Sales 2021 315x
Nbr of Employees 15
Free-Float 71,1%
More Financials
Company
Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational... 
Sector
Holding Companies
Calendar
04/28Earnings Release
More about the company
All news about ARIX BIOSCIENCE PLC
07:41aARIX BIOSCIENCE : Managing Director to Step Down
MT
02:01aARIX BIOSCIENCE : Investment team changes
DJ
01/12ARIX BIOSCIENCE : Artios Pharma Expands US Leadership Team with the Appointment ..
PU
01/12Harpoon announces closing of public offering
DJ
01/06ARIX BIOSCIENCE : Imara reports Phase 2a clinical trial results of -2-
DJ
01/06ARIX BIOSCIENCE : Atox Bio Announces FDA Acceptance to File the NDA for Reltecim..
PU
01/06ARIX BIOSCIENCE : Autolus provides business outlook for 2021 and -2-
DJ
01/06Autolus provides business outlook for 2021 and 2022
DJ
2020ARIX BIOSCIENCE : Completion of sale of VelosBio
AQ
2020Director Share Purchase
DJ
2020Arix Bioscience Closes $2.75 Billion Sale Of Portfolio Company VelosBio To Me..
MT
2020ARIX BIOSCIENCE : Completion of sale of VelosBio
DJ
2020ARIX BIOSCIENCE : Portfolio Company's New Drug Application for Reltecimod Accept..
MT
2020ARIX BIOSCIENCE : Atox Bio Announces FDA Acceptance to File the NDA for Reltecim..
PU
2020ARIX BIOSCIENCE : Atox Bio announces FDA acceptance of New Drug -2-
DJ
More news
News in other languages on ARIX BIOSCIENCE PLC
2020Les marchés s'en fichent, vraiment ?
2020AVIS D'ANALYSTES DU JOUR : ArcelorMittal, Casino, Crédit Agricole, Getinge, Lanx..
2020AVIS D'ANALYSTES DU JOUR : ArcelorMittal, AXA, BNP Paribas, Clariant, HelloFresh..
2020Moderna fait son comeback estival
2019STOCK MARKET PARIS : Des marchés inquiets, mais pas trop
More news
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 233,67 GBX
Last Close Price 205,00 GBX
Spread / Highest target 30,2%
Spread / Average Target 14,0%
Spread / Lowest Target 1,46%
EPS Revisions
Managers and Directors
NameTitle
Jonathan Tobin Co-Managing Director
Christian Schetter Co-Managing Director
Naseem Amin Executive Chairman
Robert Lyne COO, Secretary & General Counsel
Marcus Karia Group Finance Director
Sector and Competitors
1st jan.Capitalization (M$)
ARIX BIOSCIENCE PLC-6.39%364
CK HUTCHISON HOLDINGS LIMITED5.64%28 275
INDUSTRIVÄRDEN AB3.28%14 490
KINNEVIK AB1.00%13 904
LIFCO AB (PUBL)3.61%8 869
SOMFY SA7.50%6 194